Cervical Cancer Vaccine Candidate Advances

Nykode Therapeutics ASA today announced that it had expanded the clinical collaboration and supply agreement with Roche to cover the evaluation of VB10.16, an off-the-shelf therapeutic cancer vaccine candidate in development for the treatment of human papillomavirus type 16 (HPV16)-positive cancers.

This collaboration, unveiled on June 1, 2023, is evaluating the combination with Roche’s cancer immunotherapy atezolizumab in patients with advanced cervical cancer who have progressed on pembrolizumab plus chemotherapy +/- bevacizumab as first-line treatment.

The VB-C-04 clinical trial is expected to be initiated in the U.S. in the fourth quarter of 2023 with registrational intent, which provides a potential fast-to-market path.

“We look forward to expanding our collaboration with Roche to bring the combination of VB10.16 and atezolizumab to cervical cancer patients with limited treatment options. Cervical cancer has a poor prognosis, and the recent positive clinical data from VB-C-02 has strengthened our commitment to contribute to a well-tolerated treatment that can potentially prolong the life of these women. The trial provides a potential fast path to market for VB10.16,” commented Michael Engsig, CEO of Nykode Therapeutics, in a press release.

Precision Vaccinations post other cervical cancer vaccine updates.